Lipocine Inc. (LPCN)
NASDAQ: LPCN · Real-Time Price · USD
4.710
-0.050 (-1.05%)
At close: Nov 20, 2024, 4:00 PM
4.930
+0.220 (4.67%)
After-hours: Nov 20, 2024, 4:35 PM EST
Lipocine Employees
Lipocine had 17 employees as of December 31, 2023. The number of employees did not change compared to the previous year.
Employees
17
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$466,054
Profits / Employee
-$238,593
Market Cap
25.19M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Allurion Technologies | 504 |
DarioHealth | 294 |
BioXcel Therapeutics | 74 |
IGC Pharma | 67 |
Athira Pharma | 67 |
Equillium | 44 |
Longeveron | 24 |
Ocean Biomedical | 9 |
LPCN News
- 3 days ago - Lipocine Announces Publication and Discussion of LPCN 1148 Manuscript at The Liver Meeting 2024 Editor's Cut Session - PRNewsWire
- 14 days ago - Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2024 - PRNewsWire
- 21 days ago - Lipocine Announces Distribution and License Agreement with SPC Korea to Commercialize TLANDO® in South Korea - PRNewsWire
- 6 weeks ago - Lipocine Announces Positive Oral Brexanolone Quantitative EEG Results - PRNewsWire
- 6 weeks ago - Lipocine Announces Supply and Distribution Agreement with Pharmalink to Commercialize TLANDO® in the Gulf Cooperation Council (GCC) Countries - PRNewsWire
- 7 weeks ago - Lipocine to Host Virtual KOL Event on LPCN 2401 for Improved Body Composition in Obesity Management on October 16, 2024 - PRNewsWire
- 7 weeks ago - Lipocine to Present at H.C. Wainwright 8th Annual MASH Investor Conference - PRNewsWire
- 2 months ago - Lipocine Announces Phase 2 Data on LPCN 2401 to be Presented at ObesityWeek® - PRNewsWire